About Apolomed
Founded in 2001, Apolomed is a global leader in medical aesthetic technology, operating from a modern 135,000+ square foot manufacturing center in Shanghai. For more than twenty five years, we have specialized in research, development, manufacturing, marketing, and service within the medical aesthetic field.
Every Apolomed system is engineered and produced under the highest international standards, following strict ISO13485, MDSAP, and MDR quality systems. Our technologies hold major global regulatory approvals including CE in Europe, FDA in the United States, TGA in Australia, Anvisa in Brazil, and more. These certifications give our partners confidence that they are offering devices built for true global competitiveness in safety, performance, and reliability.
Apolomed’s strength comes from advanced production machinery, a highly skilled technical workforce, and an expert quality control team. Our manufacturing capabilities consistently meet high volume requirements without compromising quality or delivery timelines. Every device undergoes a rigorous end to end quality control process to ensure stable, repeatable, world class results.
Apolomed continues to expand innovation, service, and global presence so our partners can stay ahead in the fast growing medical and aesthetic market.
Our Commitment to Excellence
For more than two decades, Shanghai Apolomed has empowered physicians, aesthetic practitioners, and business owners to capture the expanding opportunities within the global aesthetic laser market. Our complete portfolio of technologies, clinical training, and ongoing service support is built to deliver real value to every partner we work with. We focus on practical, measurable outcomes that elevate clinical standards, strengthen patient satisfaction, and enhance the long term success of each practice. Every Apolomed system is designed to help providers deliver treatments that promote wellness, confidence, and meaningful improvement in their clients’ quality of life.
Global Presence
Apolomed technologies are trusted by medical and aesthetic professionals around the world. Our systems are actively used in more than fifty countries through a strong network of international distributors across North and South America, Europe, the Middle East, Oceania, and Asia. This global footprint reflects our dedication to consistent quality, reliable service, and long term partnerships.
We follow a clear guiding philosophy: focus on true product value, grow through uncompromising quality, and continually advance through innovation. At Apolomed, we believe technology should inspire, elevate the standard of care, and lead the direction of modern aesthetic practice.
Company History and Milestones
2001: Apolomed was founded and created.
2011: Received its first U.S FDA certification (510k).
2014: Listed for the first time on the Shanghai Equity Exchange (SEE, stock code: 100243).
2016: Became certified with CE mark & ISO 134885 – TUV Rheinland (0197) and passed SGS ROHS certification.
2017: Apolomed’s first picosecond laser, the HS-298, was launched.
2018: Apolomed obtained its TGA certification in Australia.
2020: Received its first ANVISA certification in Brazil.
2022: Launched its new product line of the first dual picosecond and nanosecond laser, the HS-298N.
2023: Apolomed relocated their facility and expanded to an over 7,500 m2 facility. All products were upgraded with a new sheet metal enclosure.
2024: Apolomed passed its first MDSAP certification and launched the HS-232, its first 1550+1940nm laser system. Facilities successfully expanded to over 12,500 m2.
2025: Apolomed is expecting to receive its 14th U.S FDA certification. Opened its first distribution center/service center in the U.S (NYC – Long Island).